Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?

被引：1
作者：
Bravaccini, Sara [1 ]
Bronte, Giuseppe [2 ]
机构：
[1] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Biosci Lab, Meldola, Italy
[2] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Dept Med Oncol, Meldola, Italy
来源：
CANCER CYTOPATHOLOGY | 2018年 / 126卷 / 09期
关键词：
D O I：
10.1002/cncy.22033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：817 / 818
页数：2
相关论文
共 5 条
[1]  
European Medicines Agency, KEYTR PEMBR
[2]  
Midha A, 2016, ASCO M, V34, P3025
[3]   Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis [J].
Pan, Zhen-Kui ;
Ye, Feng ;
Wu, Xuan ;
An, Han-Xiang ;
Wu, Jing-Xun .
JOURNAL OF THORACIC DISEASE, 2015, 7 (03) :462-470
[4]   Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas [J].
Russell-Goldman, Eleanor ;
Kravets, Sasha ;
Dahlberg, Suzanne E. ;
Sholl, Lynette M. ;
Vivero, Marina .
CANCER CYTOPATHOLOGY, 2018, 126 (04) :253-263
[5]   FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1 [J].
Sul, Joohee ;
Blumenthal, Gideon M. ;
Jiang, Xiaoping ;
He, Kun ;
Keegan, Patricia ;
Pazdur, Richard .
ONCOLOGIST, 2016, 21 (05) :643-650
1